Various therapeutic agents are available for the treatment of COVID-19. Yoko Tanino and colleagues reported results of an investigation of the emergence of dual-drug resistance in a kidney transplant recipient who received sotrovimab from day 0 and remdesivir (RDV) from days 8 to 17. The researchers sequenced the whole viral genomes from nasopharyngeal swabs taken on day 0 and at seven points following the start of treatment (days 12, 19, 23, 37, 43, 48, and 58). ...
Nephrology Times
Nephrology Times delivers the latest news in kidney-related treatments and technologies with the goal of better informing care decisions and improving patient outcomes.
Advertisement
Latest News
Nephrology Times will cover the National Kidney Foundation Spring Clinical Meetings 2024 live and onsite.
The National Kidney Foundation will honor distinguished health care professionals at the 2024 Spring Clinical Meetings.
Researchers studied the effect of intensive blood pressure control on the progression of IgAN.
Researchers explored the association between CSVD and CKD plus the potential role of hypertension in this association.
With four acquisitions from Fresneius Medical Care, DaVita will become the largest dialysis provider in Latin America.
Researchers examined use of clinical decision support systems to decrease blood pressure in hypertensive patients with CKD.
The FDA gave Breakthrough Device designation to the JuxtaFlow RAD to help prevent AKI during cardiothoracic surgery.
Accurate prediction of severe outcomes of acute kidney injury remains challenging.
FILSPARI (sparsentan) has received conditional marketing authorization from the European Commission to treat IgAN in adults.
Researchers examined the roles of hyperuricemia and anemia in all-cause mortality with chronic kidney disease (CKD).
Advertisement
Podcasts
Will sparsentan prove a winner for patients with FSGS, or are we doomed to forever treat them with Acthar Gel?
We've all been guilted into ordering inpatient blood pressure meds. Tim Anderson, MD, asks, "Why?"
Review Dr. Burton Rose's writings on treatment options for hypovolemic states and hypovolemic shock.
In Print
Assessing recurrent gout risk, SARS-CoV-2 vaccine response during dialysis, plant-based diets with CKD, and more.
Special issue discusses racial inequity in living donor kidney transplant, teen BMI and CKD risk, and more
Conferences
The National Kidney Foundation's premier educational event designed for the interprofessional kidney health team
The annual scientific, educational, and networking meeting of the International Society of Nephrology
The American Society of Nephrology's annual meeting to highlight the latest scientific and medical advances in the field
The joint annual meeting of the American Society of Transplantation and the American Society of Transplant Surgeons
Expert Columns
Medicare Advantage plans are posing significant operational and financial hurdles for dialysis programs.
APRIL has emerged as a critical factor in the pathogenesis of IgAN and is the focus of several clinical development programs.
The benefit-risk ratio and considerations about unmet need are worth considering.
The choice of a billing solution, often made under the guise of cost savings, requires a thoughtful approach.
The new base rate for CY 2024 is set at $271.02, which is a 2% increase from CY 2023.
SGLT2i therapy is contraindicated in patients with type 1 diabetes mellitus (T1DM) who have CKD.
Advertisement
Advertisement
Nephrology Times Chair
Ajay K. Singh, MBBS, FRCP, MBASenior Nephrologist, Brigham and Women’s Hospital | Senior Associate Dean, Harvard Medical School
Editorial Board
Mohamed G. Atta, MD, MPHProfessor of Medicine, Johns Hopkins School of Medicine
Timothy E. Bunchman, MDProfessor and Director, Pediatric Nephrology, Transplantation, and Rheumatology, Children’s Hospital of Richmond at VCU
Suphamai Bunnapradist, MD, MSProfessor of Medicine, David Geffen School of Medicine at UCLA | Research Director, Kidney Transplant Program, UCLA
Fernando C. Fervenza, MD, PhDProfessor of Medicine, Division of Nephrology and Hypertension, Mayo Clinic
Kenneth A. Liss, DOPartner, Hypertension and Nephrology Association, Eatontown, NJ
Joel M. Topf, MD, FACPAssistant Clinical Professor of Medicine, Oakland University William Beaumont School of Medicine
